339 related articles for article (PubMed ID: 15373067)
1. [Approval of a new nucleoside. Component of complete once daily regimen].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():91. PubMed ID: 15373067
[No Abstract] [Full Text] [Related]
2. [Improved long-term success. New nucleoside for once daily combinations].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():31-3. PubMed ID: 15373043
[No Abstract] [Full Text] [Related]
3. Antiretroviral activity of emtricitabine, a potent nucleoside reverse transcriptase inhibitor.
Richman DD
Antivir Ther; 2001 Jun; 6(2):83-8. PubMed ID: 11491420
[No Abstract] [Full Text] [Related]
4. Nonnucleoside reverse transcriptase inhibitors.
Murphy RL
AIDS Clin Care; 1997 Oct; 9(10):75-7, 79. PubMed ID: 11364757
[TBL] [Abstract][Full Text] [Related]
5. 96-week CASTLE data show similar efficacy results.
AIDS Patient Care STDS; 2008 Nov; 22(11):918. PubMed ID: 19043840
[No Abstract] [Full Text] [Related]
6. Emtricitabine: new preparation. An antiretroviral very similar to lamivudine.
Prescrire Int; 2005 Apr; 14(76):54-6. PubMed ID: 15875341
[TBL] [Abstract][Full Text] [Related]
7. FDA notifications. NRTI Emtriva receives FDA approval.
AIDS Alert; 2003 Oct; 18(10):131-2. PubMed ID: 14686301
[TBL] [Abstract][Full Text] [Related]
8. Nucleoside analogues in 2008.
Warwick Z; Churchill D
J HIV Ther; 2008 Mar; 13(1):3-8. PubMed ID: 18953267
[No Abstract] [Full Text] [Related]
9. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
[TBL] [Abstract][Full Text] [Related]
10. [New fixed once daily combination as nucleoside backbone. Basis for long-term therapy success].
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():66-8. PubMed ID: 16385881
[No Abstract] [Full Text] [Related]
11. Lamivudine for the treatment of HIV.
Kumar PN; Patel P
Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):105-14. PubMed ID: 20001611
[TBL] [Abstract][Full Text] [Related]
12. [Tenofovir in Study 903. Also effective and tolerable in first-line therapy].
MMW Fortschr Med; 2002 Aug; 144(33-34):61. PubMed ID: 12380158
[No Abstract] [Full Text] [Related]
13. [Favorable new data for nevirapine. Antiretroviral effect confirmed--and also lipid profile].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():58-60. PubMed ID: 15373051
[No Abstract] [Full Text] [Related]
14. Efavirenz + emtricitabine + tenofovir: new combination. HIV infection: do not modify ongoing therapy just to use one less tablet. Better adherence than with separate dosing has not been demonstrated, while reduced efficacy is plausible.
Prescrire Int; 2009 Jun; 18(101):105. PubMed ID: 19637416
[No Abstract] [Full Text] [Related]
15. New antiretroviral drugs, part II: NRTIs, NNRTIs, and beyond.
Murphy RL
AIDS Clin Care; 1999 Jun; 11(6):47-9, 51, 53-4. PubMed ID: 11366882
[TBL] [Abstract][Full Text] [Related]
16. A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients.
Ananworanich J; Hill A; Siangphoe U; Ruxrungtham K; Prasithsirikul W; Chetchotisakd P; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; Nuesch R; Cooper DA; Hirschel B;
Antivir Ther; 2005; 10(6):761-7. PubMed ID: 16218176
[TBL] [Abstract][Full Text] [Related]
17. [Reliability: nevirapine. Highly effective + favorable influence on lipid profile].
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():42-3. PubMed ID: 16385872
[No Abstract] [Full Text] [Related]
18. Antiretroviral resistance.
Geretti AM
J HIV Ther; 2006 Dec; 11(4):72-3. PubMed ID: 17578209
[No Abstract] [Full Text] [Related]
19. Emtricitabine intolerance in treatment-experienced patients switched from lamivudine: a method of assessing toxicity.
Pollock K; Stebbing J; Bower M; Gazzard B; Nelson M
J Antimicrob Chemother; 2006 Jul; 58(1):227-8. PubMed ID: 16684800
[No Abstract] [Full Text] [Related]
20. Switch study of nevirapine.
AIDS Patient Care STDS; 2000 Dec; 14(12):672. PubMed ID: 11187109
[No Abstract] [Full Text] [Related]
[Next] [New Search]
